Printer Friendly

HPV vaccine may stem vulvar, vaginal cancers.

ATLANTA -- The recently approved quadrivalent human papillomavirus vaccine shown to be effective for preventing most HPV-related cervical cancers may also prevent most vulvar and vaginal cancers, Dr. Jorma Paavonen reported at the annual meeting of the American Society of Clinical Oncology.

The vaccine (Gardisil, Merck & Co.) received approval from the U.S. Food and Drug Administration in June, after winning unanimous support from an FDA advisory panel.

Gardisil targets HPV 6 and 11, which are associated with anogenital warts, and HPV 16 and 18, which cause most cervical cancers. HPV 16 and 18 are also the most common causes of vulvar and vaginal cancers, said Dr. Paavonen, professor and chief physician in obstetrics and gynecology at the University of Helsinki, Finland.

The FUTURE II study was a combined analysis of data from three randomized, placebo-controlled trials that studied the impact of the vaccine on rates of HPV 16- and 18-related vulvar and vaginal intraep-ithelial neoplasia grade 2/3. FUTURE II showed that the vaccine was 100% effective up to 2 years of follow-up for preventing these precancerous lesions, said Dr. Paavonen, who has served as a consultant to and received research funding from Merck.

These trials randomized 18,150 women aged 16-26 to receive either the vaccine or placebo. Vaccination occurred at day 1 and at 2 and 6 months. Genital tract specimens were obtained at day 1 and then at 6- to 12-month intervals for up to 48 months, with colposcopy performed as needed following algorithm-based referrals.

On per-protocol analysis, there were 10 cases of vulvar intraepithelial neoplasia (VIN) 2/3 or vaginal intraepithelial neoplasia (VaIN) 2/3 in the placebo group, and none in the vaccine group, at an average of 18 months of follow-up. On modified intention-to-treat analysis, there were 24 histologically confirmed cases of VIN 2/3 or VaIN 2/3 in the placebo group, at an average of 2 years of follow-up.

"The burden of HPV disease is not restricted to the cervix. HPV is present in nearly 80% of the 6,000 cases of vaginal and vulvar cancers diagnosed in the United States each year," Dr. Paavonen said.

BY SHARON WORCESTER

Southeast Bureau
COPYRIGHT 2006 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Infectious Diseases
Author:Worcester, Sharon
Publication:Internal Medicine News
Geographic Code:1USA
Date:Jul 15, 2006
Words:359
Previous Article:Statins may decrease cataract risk.
Next Article:Precollege rush for Menactra drove distribution during the first year.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |